CTXR — Citius Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $24.67m
- $22.08m
Annual income statement for Citius Pharmaceuticals, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 17.7 | 23.4 | 33.3 | 33.1 | 39.6 |
| Operating Profit | -17.7 | -23.4 | -33.3 | -33.1 | -39.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -17.5 | -23.1 | -33.1 | -32 | -38.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17.5 | -23.1 | -33.6 | -32.5 | -39.4 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.5 | -23.1 | -33.6 | -32.5 | -39.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.5 | -24.5 | -33.6 | -33.7 | -40.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -11.2 | -5.68 | -5.76 | -5.95 | -6.2 |